Repligen
RGEN
S$153.88
Share price
-1.71%
Change (1 day)
-16.97%
Change (1 year)
Categories
Earnings for Repligen (RGEN)
Earnings in 2025 (TTM): -S$3.07 Million
According to Repligen 's latest financial reports the company's current earnings are S$0.65 Billion. In 2024 the company made an earning of -S$8.11 Million a decrease over its 2023 earnings that were of S$62.31 Million. The earnings displayed on this page is the company's Pretax Income.
Earnings history for Repligen from 1985 to 2025
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2025 (TTM)  | -S$3.07 Million | -62.19% |
| 2024 | -S$8.11 Million | -113.01% |
| 2023 | S$62.31 M | -78.01% |
| 2022 | S$0.28 B | 33.37% |
| 2021 | S$0.21 B | 131.52% |
| 2020 | S$91.76 M | 101.31% |
| 2019 | S$45.58 M | 25.93% |
| 2018 | S$36.19 M | 105.61% |
| 2017 | S$17.6 M | -11.46% |
| 2016 | S$19.88 M | 14.91% |
| 2015 | S$17.3 M | 20.26% |
| 2014 | S$14.38 M | -51.49% |
| 2013 | S$29.66 M | 90.98% |
| 2012 | S$15.53 M | |
| 2010 | S$0.22 M | -103.81% |
| 2009 | -S$5.9 Million | -223.84% |
| 2008 | S$4.76 M | |
| 2006 | -S$3.21 Million | 229.64% |
| 2005 | -S$0.98 Million | -89.16% |
| 2004 | -S$8.96 Million | -16.86% |
| 2003 | -S$10.78 Million | 88.72% |
| 2002 | -S$5.71 Million | -27.88% |
| 2001 | -S$7.92 Million | -1.74% |
| 2000 | -S$8.06 Million | 85.93% |
| 1999 | -S$4.34 Million | 159.16% |
| 1998 | -S$1.68 Million | 85.71% |
| 1997 | -S$0.91 Million | -70.83% |
| 1996 | -S$3.09 Million | -72.41% |
| 1995 | -S$11.19 Million | -60.63% |
| 1994 | -S$28.43 Million | 45.39% |
| 1993 | -S$19.55 Million | 39.45% |
| 1992 | -S$14.02 Million | -32.3% |
| 1991 | -S$20.71 Million | 6.62% |
| 1990 | -S$19.43 Million | 1577.78% |
| 1989 | -S$1.16 Million | -57.14% |
| 1988 | -S$2.71 Million | -362.5% |
| 1987 | S$1.02 M | -130.77% |
| 1986 | -S$3.35 Million | 136.36% |
| 1985 | -S$1.42 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Novavax NVAX | S$0.65 B | -27,904.14% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | S$0.86 B | -36,846.87% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | S$0.68 B | -29,037.33% | 🇺🇸 USA |
 General Electric GE | S$11.33 B | -480,263.49% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | S$9.09 B | -385,277.11% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | S$7.85 B | -332,961.04% | 🇺🇸 USA |
 Pfizer PFE | S$13.29 B | -563,642.23% | 🇺🇸 USA |
 Bio-Techne TECH | S$0.22 B | -9,463.60% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | -S$0.11 Billion | 4,308.66% | 🇺🇸 USA |
 Charles River Laboratories
CRL | S$38.68 M | -1,739.29% | 🇺🇸 USA |